Valacyclovir for HSV-1-Positive Parkinson's Disease

Valacyclovir for Parkinson's Disease: HSV-1 Reactivation-Targeting Therapy

Overview

Trial Overview

| Attribute | Value |
|-----------|-------|
| Trial Name | VALACY-PD (Valacyclovir for Parkinson's Disease) |
| Phase | Phase 2 |
| Design | Randomized, double-blind, placebo-controlled |
| Sample Size | 200 participants (100 per arm) |
| Duration | 12 months treatment, 3 months follow-up |
| Primary Endpoint | Change in UPDRS-III score at 12 months |
| Secondary Endpoints | HSV-1 antibody titers, inflammatory markers, non-motor symptoms |
| Sponsor | Proposed academic consortium |
| ClinicalTrials.gov ID | To be assigned |

Rationale and Background

Scientific Basis

Valacyclovir for Parkinson's Disease: HSV-1 Reactivation-Targeting Therapy

Overview

Trial Overview

| Attribute | Value |
|-----------|-------|
| Trial Name | VALACY-PD (Valacyclovir for Parkinson's Disease) |
| Phase | Phase 2 |
| Design | Randomized, double-blind, placebo-controlled |
| Sample Size | 200 participants (100 per arm) |
| Duration | 12 months treatment, 3 months follow-up |
| Primary Endpoint | Change in UPDRS-III score at 12 months |
| Secondary Endpoints | HSV-1 antibody titers, inflammatory markers, non-motor symptoms |
| Sponsor | Proposed academic consortium |
| ClinicalTrials.gov ID | To be assigned |

Rationale and Background

Scientific Basis

This clinical trial tests the Viral Trigger Hypothesis in Parkinson's Disease, which proposes that chronic or repeated reactivation of herpes simplex virus type 1 (HSV-1) contributes to neuroinflammation and dopaminergic neurodegeneration. The trial evaluates whether suppressing viral reactivation with valacyclovir can slow disease progression in early-stage PD patients.

HSV-1 and Parkinson's Disease: Evidence Summary

Epidemiological and mechanistic studies support the link between HSV-1 and PD:

Rationale for Valacyclovir

• Pro-drug of acyclovir: Valacyclovir has ~10x better oral bioavailability than acyclovir
• HSV-1 specificity: Effective against herpes simplex viruses
• Safety profile: Well-established safety in treating herpes infections
• Prior use in neurological conditions: Has been studied in herpes encephalitis and as adjuvant therapy

Hypothesis

Primary Hypothesis: Chronic HSV-1 reactivation contributes to neuroinflammation and dopaminergic neurodegeneration in PD. Suppressing viral reactivation with valacyclovir will reduce inflammatory burden and slow motor progression.

Secondary Hypotheses:

Study Design

Type

• Randomized, double-blind, placebo-controlled, parallel-group trial
• 1:1 allocation ratio

Population

Inclusion Criteria:

Exclusion Criteria:

Stratification Factors

• Age (<65 vs ≥65 years)
• Disease duration (<18 months vs ≥18 months)
• Baseline UPDRS-III score

Intervention

Treatment Arm

• Drug: Valacyclovir 1g oral tablet
• Dose: 1g twice daily (2g total daily)
• Duration: 12 months
• Rationale: Suppresses HSV-1 replication and reduces reactivation frequency

Control Arm

• Drug: Placebo (matched tablet appearance)
• Dose: Twice daily
• Duration: 12 months

Concomitant Medications

• Participants continue standard antiparkinsonian therapy
• Avoid new HSV-1-active medications (acyclovir, famciclovir, penciclovir)
• Document all concomitant medications

Endpoints

Primary Endpoints

| Endpoint | Measurement | Timepoints | Justification |
|----------|-------------|------------|---------------|
| Motor progression | UPDRS Part III (OFF medication) | Baseline, 6, 12 months | Standard PD progression measure |
| Viral reactivation burden | HSV-1 IgG avidity index | Baseline, 3, 6, 9, 12 months | Measures viral activity |
| Systemic inflammation | Serum IL-6, TNF-α | Baseline, 6, 12 months | Key inflammatory mediators |

Secondary Endpoints

| Endpoint | Measurement | Timepoints |
|----------|-------------|------------|
| Non-motor symptoms | Non-Motor Symptoms Scale (NMSS) | Baseline, 6, 12 months |
| Quality of life | Parkinson's Disease Questionnaire-39 (PDQ-39) | Baseline, 6, 12 months |
| Cognitive function | Montreal Cognitive Assessment (MoCA) | Baseline, 6, 12 months |
| Autonomic function | SCOPA-AUT | Baseline, 6, 12 months |
| Depression | Geriatric Depression Scale (GDS-15) | Baseline, 6, 12 months |
| Dopaminergic imaging | DaTSPECT (optional subset, n=40) | Baseline, 12 months |
| HSV-1 serostatus | HSV-1 IgG, IgM | Baseline, 12 months |

Safety Endpoints

• Adverse events (AE) and serious adverse events (SAE)
• Liver function tests (ALT, AST, bilirubin)
• Renal function (creatinine, eGFR)
• Complete blood count

Statistical Analysis

Sample Size Justification

Assumptions:

• UPDRS-III progression in placebo group: 5 points/year (based on PD progression literature)
• Expected treatment effect: 40% reduction in progression (2 points)
• Standard deviation: 8 points
• Power: 80%
• Alpha: 0.05 (two-sided)
• 20% dropout rate

Primary Analysis

• Mixed-effects model for repeated measures (MMRM)
• Treatment effect estimated as difference in least squares means
• Primary analysis: ITT population

Secondary Analyses

• Per-protocol analysis
• Subgroup analyses by HSV-1 serostatus
• Correlation analyses: inflammatory markers vs. UPDRS progression
• Completer analysis

Timeline

| Milestone | Timeframe |
|-----------|-----------|
| Protocol development | Months 1-3 |
| IRB approval | Months 3-4 |
| Site preparation and recruitment start | Months 4-5 |
| Enrollment completion | Month 20 |
| Treatment completion | Month 32 |
| Follow-up completion | Month 35 |
| Database lock | Month 36 |
| Primary results | Month 38 |

Safety Monitoring

Adverse Event Monitoring

• All adverse events recorded throughout study
• AE severity graded per CTCAE v5.0
• Causality assessment by investigator

Stopping Rules

• >3-fold increase in ALT/AST: Hold study drug, monitor
• >5-fold increase: Permanent discontinuation
• Serious adverse events: Report within 24 hours

Data Safety Monitoring Board (DSMB)

• Interim safety analysis at 6 months (n=100)
• Annual review of safety data
• Pre-specified stopping rules for efficacy
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/genes/ar)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

See Also

• [Lateral Habenula in Depression](/wiki/cell-types-lateral-habenula-in-depression) — associated_with
• [Spinal Trigeminal Nucleus in Neurodegeneration](/wiki/cell-types-spinal-trigeminal-nucleus-neurodegeneration) — causes
• [Neurodegeneration](/wiki/diseases-neurodegeneration) — causes
• [Synucleinopathies](/wiki/mechanisms-synucleinopathies) — contributes_to
• [SNCA — Alpha-Synuclein](/wiki/genes-snca) — causes

Pathway Diagram

The following diagram shows the key molecular relationships involving Valacyclovir for HSV-1-Positive Parkinson's Disease discovered through SciDEX knowledge graph analysis: